Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing reference ranges for non-HLA antibodies: Comparative analysis of blood donors and kidney transplant candidates.

Transplant immunology·2026
Same author

Kidney transplant rejection despite zero eplet DR / DQ mismatch: A case report.

Human immunology·2025
Same author

Testing controls demonstrates a high prevalence of non-HLA antibody positivity using pre-defined cutoff threshold in a bead-based assay using healthy control population.

Transplant immunology·2025
Same author

Hemovigilance and the Notify Library.

Immunohematology·2021
Same author

Identifying a newly discovered HLA-C allele, HLA-C*02:138.

HLA·2018
Same author

Identifying a newly discovered HLA-C allele: HLA-C*07:607.

HLA·2018
Same journal

Indian Expert Consensus on Allergic Rhinitis in Women: A Modified Delphi Survey.

The Journal of the Association of Physicians of India·2026
Same journal

Systematic Review of Topical Capsaicin 0.075% for the Treatment of Neuropathic Pain: Efficacy, Safety, and Tolerability.

The Journal of the Association of Physicians of India·2026
Same journal

Sodium-Glucose Cotransporter 2 Inhibitors in Kidney Diseases Other Than That Due to Diabetes: Benefits in Composite Renal Outcomes Driven by Immunoglobulin A Nephropathy.

The Journal of the Association of Physicians of India·2026
Same journal

<i>Fasciolopsis buski</i> Diagnosed by Upper Gastrointestinal Endoscopy.

The Journal of the Association of Physicians of India·2026
Same journal

"Academic Overdose" among Healthcare Professionals.

The Journal of the Association of Physicians of India·2026
Same journal

Respiratory Examination for Postgraduate Residents: Unrevealing Expert's Questions and Answers.

The Journal of the Association of Physicians of India·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Does 'ENHANCE' diminish confidence in ezetimibe?

M J Gandhi

    The Journal of the Association of Physicians of India
    |December 18, 2008
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Cholesterol Efflux Assay
    07:54

    Cholesterol Efflux Assay

    Published on: March 6, 2012

    Related Experiment Videos

    Last Updated: Jun 27, 2026

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
    09:15

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

    Published on: November 10, 2017

    Cholesterol Efflux Assay
    07:54

    Cholesterol Efflux Assay

    Published on: March 6, 2012